Zealand Pharma Net Income 2017-2021 | ZEAL

Zealand Pharma net income from 2017 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Zealand Pharma Annual Net Income
(Millions of US $)
2020 $-130
2019 $-86
2018 $92
2017 $-41
2016 $-23
Zealand Pharma Quarterly Net Income
(Millions of US $)
2021-06-30 $-48
2021-03-31 $-39
2020-12-31 $-59
2020-09-30 $-36
2020-06-30 $-9
2020-03-31 $-27
2019-12-31 $-29
2019-09-30 $-17
2019-06-30 $-21
2019-03-31 $-19
2018-12-31 $-17
2018-09-30 $144
2018-06-30 $-20
2018-03-31 $-15
2017-12-31 $-17
2017-09-30 $-7
2017-06-30 $-14
2017-03-31 $-4
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.334B $0.054B
Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00